Health · World

AbbVie Receives European Approval for Lymphoma Treatment

1 sourceFirst reported 5 days agoUpdated 5 days ago

AI summary: catch up in 20 seconds

AbbVie announced that the European Commission approved epcoritamab® in combination with lenalidomide and rituximab.
The treatment is indicated for relapsed or resistant follicular lymphoma.
This approval adds a new option for patients facing this type of cancer in Europe.
Epcoritamab® is part of AbbVie's ongoing commitment to oncology research and development.

Generated by AI from the 1 sources below · always verify with the originals

AI summary: catch up in 20 seconds

Summarising the coverage…

Generated by AI from the 1 sources below · always verify with the originals

All coverage (1)

In this storyEU Affairs

Sign in to join the discussion.

No comments yet. Be the first to join the discussion.

AI summary: catch up in 20 seconds

AbbVie announced that the European Commission approved epcoritamab® in combination with lenalidomide and rituximab.
The treatment is indicated for relapsed or resistant follicular lymphoma.
This approval adds a new option for patients facing this type of cancer in Europe.
Epcoritamab® is part of AbbVie's ongoing commitment to oncology research and development.

Generated by AI from the 1 sources below · always verify with the originals